Esophageal Neoplasms

"Esophageal Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the ESOPHAGUS.

Descriptor ID	D004938
MeSH Number(s)	C04.588.274.476.205 C04.588.443.353 C06.301.371.205 C06.405.117.430 C06.405.249.205
Concept/Terms	Esophageal Neoplasms Esophageal Neoplasms Esophageal Neoplasm Neoplasm, Esophageal Esophagus Neoplasm Esophagus Neoplasms Neoplasm, Esophagus Neoplasms, Esophagus Neoplasms, Esophageal Cancer of Esophagus Cancer of Esophagus Cancer of the Esophagus Esophagus Cancer Cancer, Esophagus Cancers, Esophagus Esophagus Cancers Esophageal Cancer Cancer, Esophageal Cancers, Esophageal Esophageal Cancers

Below are MeSH descriptors whose meaning is more general than "Esophageal Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Digestive System Neoplasms [C04.588.274]
Gastrointestinal Neoplasms [C04.588.274.476]
Esophageal Neoplasms [C04.588.274.476.205]
Head and Neck Neoplasms [C04.588.443]
Esophageal Neoplasms [C04.588.443.353]
Digestive System Diseases [C06]
Digestive System Neoplasms [C06.301]
Gastrointestinal Neoplasms [C06.301.371]
Esophageal Neoplasms [C06.301.371.205]
Gastrointestinal Diseases [C06.405]
Esophageal Diseases [C06.405.117]
Esophageal Neoplasms [C06.405.117.430]
Gastrointestinal Neoplasms [C06.405.249]
Esophageal Neoplasms [C06.405.249.205]

Below are MeSH descriptors whose meaning is more specific than "Esophageal Neoplasms".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Esophageal Neoplasms" by people in this website by year, and whether "Esophageal Neoplasms" was a major or minor topic of these publications.

Bar chart showing 125 publications over 29 distinct years, with a maximum of 14 publications in 2009

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1998	1	0	1
1999	1	0	1
2000	2	0	2
2001	1	0	1
2002	2	0	2
2003	1	0	1
2004	3	3	6
2005	3	0	3
2006	2	1	3
2007	4	1	5
2008	7	0	7
2009	14	0	14
2010	8	0	8
2011	6	1	7
2012	5	0	5
2013	5	0	5
2014	5	0	5
2015	6	0	6
2016	4	1	5
2017	4	0	4
2018	3	1	4
2019	4	0	4
2020	5	0	5
2021	4	0	4
2022	4	0	4
2023	3	0	3
2024	6	1	7
2025	2	0	2

Below are the most recent publications written about "Esophageal Neoplasms" by people in Profiles.

Matsui K, Miyawaki Y, Kobayashi R, Yoshizawa M, Toriumi T, Ebara G, Sato H, Sakuramoto S. Clinical advantages of two vs. three courses of neoadjuvant chemotherapy using docetaxel?+?cisplatin?+?5-fluorouracil to improve preoperative nutritional status and mitigate decreasing skeletal muscle in resectable esophageal cancer. Int J Clin Oncol. 2025 Oct; 30(10):1992-2002.

View in: PubMed
Cruz-Correa M, Xu RH, Moehler M, Oh DY, Kato K, Spigel D, Arkenau HT, Tabernero J, Zimina AV, Bai Y, Shi J, Lee KW, Hirano H, Wyrwicz L, Cid RP, Xu H, Sheng T, Barnes G. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study. Curr Med Res Opin. 2025 Jun; 41(6):1007-1016.

View in: PubMed
Nemati S, Islami F, Kamangar F, Poustchi H, Roshandel G, Shakeri R, Domingues A, Khoshnia M, Gharavi A, Brennan P, Abnet CC, Dawsey SM, Boffetta P, Malekzadeh R, Sheikh M. Improvement of esophageal cancer survival in Northeast Iran: A two-decade journey in a high-risk, low- resource region. PLoS One. 2024; 19(9):e0310842.

View in: PubMed
Inoue-Choi M, Freedman ND, Etemadi A, Hashemian M, Brennan P, Roshandel G, Poustchi H, Boffetta P, Kamangar F, Amiriani T, Norouzi A, Dawsey S, Malekzadeh R, Abnet CC. One-carbon metabolism biomarkers and upper gastrointestinal cancer in the Golestan Cohort Study. Int J Cancer. 2024 Dec 01; 155(11):1944-1957.

View in: PubMed
Dash S, Hanson S, King B, Nyswaner K, Foss K, Tesi N, Harvey MJB, Navarro-Marchal SA, Woods A, Poradosu E, Unciti-Broceta A, Carragher NO, Brognard J. The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas. J Biol Chem. 2024 09; 300(9):107615.

View in: PubMed
Xia WF, Zheng XL, Liu WY, Huang YT, Wen CJ, Zhou HH, Wu QC, Wu LX. Romidepsin exhibits anti-esophageal squamous cell carcinoma activity through the DDIT4-mTORC1 pathway. Cancer Gene Ther. 2024 May; 31(5):778-789.

View in: PubMed
Etemadi A, Poustchi H, Chang CM, Calafat AM, Blount BC, Bhandari D, Wang L, Roshandel G, Alexandridis A, Botelho JC, Xia B, Wang Y, Sosnoff CS, Feng J, Nalini M, Khoshnia M, Pourshams A, Sotoudeh M, Gail MH, Dawsey SM, Kamangar F, Boffetta P, Brennan P, Abnet CC, Malekzadeh R, Freedman ND. Exposure to polycyclic aromatic hydrocarbons, volatile organic compounds, and tobacco-specific nitrosamines and incidence of esophageal cancer. J Natl Cancer Inst. 2024 03 07; 116(3):379-388.

View in: PubMed
Rajasekaran N, Wang X, Ravindranathan S, Chin DJ, Tseng SY, Klakamp SL, Widmann K, Kapoor VN, Vexler V, Keegan P, Yao S, LaVallee T, Khare SD. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. Cancer Immunol Immunother. 2024 Feb 24; 73(3):60.

View in: PubMed
Kotnala S, Dhasmana A, Dhasmana S, Haque S, Yallapu MM, Tripathi MK, Jaggi M, Chauhan SC. A Systems Biology Approach Unveils a Critical Role of DPP4 in Upper Gastrointestinal Cancer Patient Outcomes. J Environ Pathol Toxicol Oncol. 2024; 43(2):43-55.

View in: PubMed
Paiboonrungruang C, Xiong Z, Lamson D, Li Y, Bowman B, Chembo J, Huang C, Li J, Livingston EW, Frank JE, Chen V, Li Y, Weissman B, Yuan H, Williams KP, Ben Major M, Chen X. Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia. Redox Biol. 2023 11; 67:102901.

View in: PubMed

People

Explore

Similar Concepts

Top Journals